Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-hydroxystaurosporine is a synthetic derivative of staurosporine with potent antineoplastic (anticancer) activity. It acts as a broad-spectrum protein kinase inhibitor, targeting multiple kinases including serine/threonine kinase AKT, calcium-dependent protein kinase C (PKC), cyclin-dependent kinases (CDKs), checkpoint kinase Chk1, and others. By inhibiting these kinases, it disrupts cell cycle progression—arresting tumor cells at the G1/S phase—and impairs DNA repair mechanisms by inhibiting the G2 checkpoint via Chk1 inhibition, ultimately leading to apoptosis. The drug has been investigated in clinical trials for various advanced solid tumors and hematologic malignancies[1][2][5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-hydroxystaurosporine.